KR20130103101A - Composition for body fat lipolysis using alginate double-layers nanoemulsions containing oleoresin capsicum - Google Patents
Composition for body fat lipolysis using alginate double-layers nanoemulsions containing oleoresin capsicum Download PDFInfo
- Publication number
- KR20130103101A KR20130103101A KR1020120024467A KR20120024467A KR20130103101A KR 20130103101 A KR20130103101 A KR 20130103101A KR 1020120024467 A KR1020120024467 A KR 1020120024467A KR 20120024467 A KR20120024467 A KR 20120024467A KR 20130103101 A KR20130103101 A KR 20130103101A
- Authority
- KR
- South Korea
- Prior art keywords
- nanoemulsion
- oleoresin capsicum
- layers
- capsicum
- body fat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 66
- 235000002566 Capsicum Nutrition 0.000 title claims abstract description 46
- 239000001390 capsicum minimum Substances 0.000 title claims abstract description 46
- 239000008601 oleoresin Substances 0.000 title claims abstract description 46
- 235000010443 alginic acid Nutrition 0.000 title claims abstract description 31
- 229920000615 alginic acid Polymers 0.000 title claims abstract description 31
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 229940072056 alginate Drugs 0.000 title claims abstract description 13
- 210000000577 adipose tissue Anatomy 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims abstract description 9
- 230000004130 lipolysis Effects 0.000 title description 7
- 240000008574 Capsicum frutescens Species 0.000 title 1
- 241000208293 Capsicum Species 0.000 claims abstract description 45
- 239000000783 alginic acid Substances 0.000 claims abstract description 18
- 229960001126 alginic acid Drugs 0.000 claims abstract description 18
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 18
- 239000011259 mixed solution Substances 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 10
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims abstract description 10
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 abstract description 15
- 235000020824 obesity Nutrition 0.000 abstract description 15
- 230000005802 health problem Effects 0.000 abstract description 5
- 206010033307 Overweight Diseases 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 210000001789 adipocyte Anatomy 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 239000002356 single layer Substances 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 239000010410 layer Substances 0.000 description 9
- 235000021588 free fatty acids Nutrition 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 230000002366 lipolytic effect Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102100030431 Fatty acid-binding protein, adipocyte Human genes 0.000 description 5
- 101001062864 Homo sapiens Fatty acid-binding protein, adipocyte Proteins 0.000 description 5
- 108010055297 Sterol Esterase Proteins 0.000 description 5
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 5
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 4
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 4
- 240000004160 Capsicum annuum Species 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000006372 lipid accumulation Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- 235000007862 Capsicum baccatum Nutrition 0.000 description 3
- 102000000019 Sterol Esterase Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000001728 capsicum frutescens Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 210000000593 adipose tissue white Anatomy 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 1
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241001491705 Macrocystis pyrifera Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101000755720 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Palmitoyltransferase akr1 Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000013190 lipid storage Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
본 발명은 올레오레진 캡시컴(Oleoresin Capsicum)을 함유한 알긴산 이중층(Double-layers) 나노에멀젼의 체지방 분해용 조성물에 관한 기술이다. 나아가, 본 발명은 올레오레진 캡시컴 및 Tween 80을 섞어 혼합액을 제조하는 제1단계; 및 상기 혼합액과 알긴산 용액을 섞어 이중층(double layers) 나노에멀젼을 제조하는 제2단계;를 포함하는 체지방 분해용 조성물의 제조방법에 관한 기술이다.
본 발명인 본 발명은 올레오레진 캡시컴(Oleoresin Capsicum)을 함유한 알긴산 이중층(Double-layers) 나노에멀젼의 체지방 분해용 조성물 및 그의 제조방법에 따르면, 과체중, 비만 등에 의한 최근 보건 문제를 해소할 수 있다는 유리한 효과가 인정된다.The present invention relates to a composition for body fat decomposition of an alginate double-layers nanoemulsion containing an oleoresin capsicum. Furthermore, the present invention comprises a first step of preparing a mixed solution by mixing the oleoresin capsicum and Tween 80; And a second step of preparing the double layers nanoemulsion by mixing the mixed solution and the alginic acid solution.
According to the present invention, a composition for decomposing body fat of an alginate double-layers nanoemulsion containing an oleoresin capsicum and a method for preparing the same can solve the recent health problems caused by overweight and obesity. The beneficial effect is that it is recognized.
Description
본 발명은 올레오레진 캡시컴(Oleoresin Capsicum)을 함유한 알긴산 이중층(Double-layers) 나노에멀젼의 체지방 분해용 조성물에 관한 기술이다. The present invention relates to a composition for body fat decomposition of an alginate double-layers nanoemulsion containing an oleoresin capsicum.
나아가, 본 발명은 올레오레진 캡시컴 및 Tween 80을 섞어 혼합액을 제조하는 제1단계; 및 상기 혼합액과 알긴산 용액을 섞어 이중층(double layers) 나노에멀젼을 제조하는 제2단계;를 포함하는 체지방 분해용 조성물의 제조방법에 관한 기술이다.Furthermore, the present invention comprises a first step of preparing a mixed solution by mixing the oleoresin capsicum and Tween 80; And a second step of preparing the double layers nanoemulsion by mixing the mixed solution and the alginic acid solution.
식습관과 생활습관의 급격한 변화로 전 세계적으로 비만 유병률이 빠르게 증가하고 있으며, 이는 심각한 건강문제로 대두되고 있다. 비만은 심장혈관질환, 인슐린 저항성, 당뇨, 고지혈증, 고혈압, 암 등 건강 문제의 위험을 증가하는 것으로 알려져 있다(Park, 2001). 요즘에는 과체중, 비만, 그리고 이와 관련된 건강문제들이 매우 흔해져서, 과거의 영양부족, 감염성 질환과 같은 공중보건 문제를 대체하고 있다(World Health Organization, 2000). 비만은 에너지 섭취와 소비의 불균형으로 인해 체내에 지방이 과도하게 축적된 상태를 말한다. 지방조직은 지질 저장과 에너지 대사를 조절하는데, 비만으로 인해 지방세포의 수가 증가하거나, 그 크기가 확장하게 된다(Ejaz et al., 2009). 특히 백색지방조직은 에너지 저장기관으로서 중성지방을 형성하며, 에너지가 부족할 경우에는 지방산을 혈류로 방출시킨다(Mercader et al., 2006).The rapid change in eating and lifestyle has led to a rapid increase in the prevalence of obesity worldwide, which is becoming a serious health problem. Obesity is known to increase the risk of health problems such as cardiovascular disease, insulin resistance, diabetes, hyperlipidemia, hypertension, and cancer (Park, 2001). Nowadays, overweight, obesity, and related health problems are becoming very common, replacing public health problems such as malnutrition and infectious diseases in the past (World Health Organization, 2000). Obesity is a condition in which fat is excessively accumulated in the body due to an imbalance between energy intake and consumption. Adipose tissue regulates lipid storage and energy metabolism. Obesity causes fat cells to increase or expand in size (Ejaz et al. al ., 2009). In particular, white adipose tissue forms triglycerides as energy storage organs, and releases fatty acids into the bloodstream when energy is scarce (Mercader et. al ., 2006).
한국국민건강영양조사(The Third Korea National Health and Nutrition Examination Survey; KNHANES Ⅲ, 2005)에 따르면, 20세 이상 성인의 비만[BMI≥25.0kg/m2] 유병률은 31.8%였다. 1995년에 14.8%였던 것과 비교하면, 지난 10년간 비만 유병율이 2배 이상 증가하였다. 따라서, 비만의 예방과 치료는 질병 발생과 사망을 줄이기 위해 중요하다 (Ejaz et al., 2009). 더욱이, 과도한 백색지방조직은 아디포카인 분비 불균형을 초래하여(Maeda et al., 2007; Walker et al., 2007) 비만과 대사 장애의 주된 원인이되므로, 이를 예방하는데 지방축적을 억제하는 것이 효과적인 방법이 될 수 있다(Joo et al., 2010).According to The Third Korea National Health and Nutrition Examination Survey (KNHANES III, 2005), the prevalence of obesity [BMI≥25.0kg / m 2 ] was 31.8% for adults over 20 years of age. Compared to 14.8% in 1995, the prevalence of obesity has more than doubled in the last decade. Therefore, prevention and treatment of obesity are important to reduce the incidence and mortality of diseases (Ejaz et. al ., 2009). Moreover, excessive white adipose tissue causes adipocaine secretion imbalance (Maeda et. al ., 2007; Walker et al ., 2007) Because it is a major cause of obesity and metabolic disorders, it may be an effective way to prevent fat accumulation in preventing it (Joo et. al ., 2010).
최근, 기능성식품을 사용하여 다양한 질병을 예방하고 치료하는 것에 대한 관심이 증가하고 있다(Crespy et al., 2004). 그리고 식품과학 분야에서는 체지방 축적억제를 통한 비만 관련 다양한 질병을 예방하는 식품 성분에 많은 관심을 가지고 연구에 집중을 기울이고 있다(Lee et al., 2009). 특히, 식품의 맛과 향, 색 등의 질감 향상을 위해 식품첨가물로 사용되는 향신료에 관한 여러 보고가 있는데(Kempaiah et al., 2006), 많은 연구들에서 향신료가 지방세포의 생성을 억제하거나(Hsu et al., 2007), 에너지 소비를 증가시킨다고 한다(Kovacs et al., 2006). 이처럼 체중조절과 비만치료에 효과적이고 안전한 식품들에 대해 관심이 높아지고 있다.Recently, there has been increasing interest in preventing and treating various diseases using functional foods (Crespy et. al ., 2004). In the field of food science, much attention is paid to food ingredients that prevent obesity-related diseases through body fat accumulation inhibition (Lee et al., 2009). In particular, there are several reports on spices used as food additives to improve the taste, aroma and color of food (Kempaiah et. al ., 2006), and many studies indicate that spices inhibit the production of fat cells (Hsu et al ., 2007) or increase energy consumption (Kovacs et. al ., 2006). As such, there is a growing interest in foods that are effective and safe for weight control and obesity treatment.
지난 몇 년 동안, 전 세계적으로 식품 나노기술에 대한 관심이 크게 고조되고 있다. 나노 기술은 100nm보다 작은 나노 규모에서 물질의 특성을 규명하고 제어하는 기술로서, 농업과 식품체계를 혁신하는데 잠재적인 기술로 여겨지고 있다. 나노 규모 구조들은 독특하고 새로운 기능적 특성을 가진다(Weiss et al., 2006). 그 예로, 식품의 안전성(Baeumner, 2004), 건강증진을 위한 기능성 식품(Weiss et al ., 2006), 식품소재의 나노특성, 생리활성 성분 전달을 위한 구조적 디자인 원리(McClements et al., 2009), 식품과학과 농업에서 나노기술 응용(Moraru et al., 2003) 등 식품 나노기술에 대한 잠재성을 언급하는 연구들이 발표되었다. 식품과 영양에서 나노기술의 응용은 수용성, 내열성, 생물학적 이용가능성, 감각적 특성 그리고 생리적 작용을 향상시키는 새로운 기능성 식품성분을 설계하고 개발하기 위한 것이다. 폴리페놀(polyphenol), 카로테노이드(carotenoid), 또는 올레오레진 캡시컴(oleoresin capsicum)등 파이토케미컬(phytochemical) 대부분의 경우는 용매에 잘 녹지 않거나, 지용성 물질이므로 경구용 생체이용률이 매우 낮다. 따라서 불안정하고 용해도가 낮은 기능성 식품의 생체이용율을 향상시키기 위한 한 가지 방법은 나노 유화액을 사용하는 것이다(Huang et al., 2010). In the last few years, interest in food nanotechnology has been increasing worldwide. Nanotechnology is a technology that characterizes and controls materials on a nanoscale smaller than 100nm and is considered a potential technology for innovation in agriculture and food systems. Nanoscale structures have unique new functional properties (Weiss et. al ., 2006). For example, food safety (Baeumner, 2004), functional foods for health promotion (Weiss et. al . , 2006), Structural Design Principles for the Delivery of Nanomaterials and Bioactive Components of Food Ingredients (McClements et al ., 2009), Nanotechnology Applications in Food Science and Agriculture (Moraru et. al ., 2003) have been published to address the potential for food nanotechnology. The application of nanotechnology in food and nutrition is to design and develop new functional food ingredients that enhance water solubility, heat resistance, bioavailability, sensory properties and physiological action. Most of the phytochemicals, such as polyphenols, carotenoids, or oleoresin capsicum, are insoluble in solvents or are fat-soluble substances and thus have low oral bioavailability. Therefore, one way to improve the bioavailability of unstable, low solubility functional foods is to use nanoemulsions (Huang et al ., 2010).
고추(capsicum annuum L.)는 우리나라뿐만 아니라 현재 전 세계 인구의 1/4정도가 매일 먹는다고 알려져 있다. 고추는 조리에 중요하게 사용되고 있으며 전 세계적으로 식품, 향신료, 악품 등으로 널리 사용되고 있다. 고추의 건조열매에서 유기용매로 추출하여 얻어지는 것이 올레오레진 캡시컴(oleoresin capsicum)이며 주로 고추의 매운맛을 내는 성분이다. 올레오레진 캡시컴의 생리활성 기능들에 관해서는 아직 잘 알려져 있지 않았으나 콜레스테롤 저하 효과가 있다는 것이 보고되었다(Gupta et al., 2002). 현재까지, 올레오레진 캡시컴의 지방분해 효과에 대한 알려져 있지 않으며, 올레오레진 켑시컴을 포함하는 알긴산 이중층 나노유화액의 지방분해 효과 또한 알려진 바가 없다. 그러므로, 본 연구 목적은 올레오레진 캡시컴을 포함하는 단일층 나노유화액과 이중층 나노유화액의 지방분해 효과에 대한 생물학적 활성을 비교하고자 한다.
Red pepper (capsicum annuum L. ) Is known not only in Korea, but now around a quarter of the world's population eats every day. Red pepper is important for cooking and is widely used as a food, spice, and bad food all over the world. Oleoresin capsicum is obtained by extracting organic solvents from dried berries of red pepper. The bioactive functions of oleoresin capsicum are not yet well known but have been reported to have cholesterol lowering effects (Gupta et al. al ., 2002). To date, no lipolytic effect of oleoresin capsicum is known, and no lipolytic effect of alginic acid bilayer nanoemulsions comprising oleoresin xicum is known. Therefore, the purpose of this study is to compare the biological activities of the lipolytic effect of monolayer nanoemulsion and bilayer nanoemulsion containing oleoresin capsicum.
이하, 본 발명의 배경문헌에 대해 개시한다.
Hereinafter, the background document of this invention is disclosed.
Baeumner A. Nanosensors identify pathogens in food. Food technol 2004;58:51-55Baeumner A. Nanosensors identify pathogens in food. Food technol 2004; 58: 51-55
Crespy V, Williamson G. A Review of the Health Effects of Green Tea Catechins in In Vivo Animal Models. J Nutr 2004;134:3431S-3440SCrespy V, Williamson G. A Review of the Health Effects of Green Tea Catechins in In Vivo Animal Models. J Nutr 2004; 134: 3431S-3440S
Ejaz A , Wu D, Kwan P, Meydani M. Curcumin Inhibits Adipogenesis in 3T3-L1 Adipocytes and Angiogenesis and Obesity in C57/BL Mice. J Nutr 2009;139:919925Ejaz A, Wu D, Kwan P, Meydani M. Curcumin Inhibits Adipogenesis in 3T3-L1 Adipocytes and Angiogenesis and Obesity in C57 / BL Mice. J Nutr 2009; 139: 919925
Gupta RS, Dixit VP, Dobhal MP. Hypocholesterolaemic effect of the oleoresin of Capsicum annum L. in gerbils (Meriones hurrianae Jerdon). Phytother Res. 2002 May;16(3):273-5.Gupta RS, Dixit VP, Dobhal MP. Hypocholesterolaemic effect of the oleoresin of Capsicum annum L. in gerbils (Meriones hurrianae Jerdon). Phytother Res. 2002 May; 16 (3): 273-5.
Hsu CL, Yen GC. Effects of capsaicin on induction of apoptosis and inhibition of adipogenesis in 3T3-L1 cells. J Agric Food Chem 2007;55:1730-1736Hsu CL, Yen GC. Effects of capsaicin on induction of apoptosis and inhibition of adipogenesis in 3T3-L1 cells. J Agric Food Chem 2007; 55: 1730-1736
Huang Q, Yu H, Ru Q. Bioavailability and Delivery of Nutraceuticals Using Nanotechnology. J Food Sci 2010;75:R50-R57Huang Q, Yu H, Ru Q. Bioavailability and Delivery of Nutraceuticals Using Nanotechnology. J Food Sci 2010; 75: R50-R57
Joo JI, Kim DH, Choi JW, Yun JW. Proteomic Analysis for Antiobesity Potential of Capsaicin on White Adipocyte Tissue in Rats Fed with High Fat Diet. J Proteome Res 2010;9:29772987Joo JI, Kim DH, Choi JW, Yun JW. Proteomic Analysis for Antiobesity Potential of Capsaicin on White Adipocyte Tissue in Rats Fed with High Fat Diet. J Proteome Res 2010; 9: 29772987
Kempaiah RK, Srinivasan K. Beneficial influence of dietary curcumin, capsaicin and garlic on erythrocyte integrity in high-fat fed rats. J Nutr Biochem 2006;17:471478Kempaiah RK, Srinivasan K. Beneficial influence of dietary curcumin, capsaicin and garlic on erythrocyte integrity in high-fat fed rats. J Nutr Biochem 2006; 17: 471478
Kovacs EMR, Mela DJ. Metabolically active functional food ingredients for weight control. Obes Rev 2006;7:5978Kovacs EMR, Mela DJ. Metabolically active functional food ingredients for weight control. Obes Rev 2006; 7: 5978
Lee MS, Kim CT, Kim Y. Green Tea ()-Epigallocatechin-3-Gallate Reduces Body Weight with Regulation of Multiple Genes Expression in Adipose Tissue of Diet-Induced Obese Mice. Ann Nutr Metab 2009;54:151157Lee MS, Kim CT, Kim Y. Green Tea () -Epigallocatechin-3-Gallate Reduces Body Weight with Regulation of Multiple Genes Expression in Adipose Tissue of Diet-Induced Obese Mice. Ann Nutr Metab 2009; 54: 151 157
Maeda H, Hosokawa M, Sashima T, Miyashita K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem 2007;55:77017706Maeda H, Hosokawa M, Sashima T, Miyashita K. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese / diabetic KK-Ay mice. J Agric Food Chem 2007; 55: 77017706
McClements DJ, Decker EA, Park Y, Weiss J. Structural Design Principles for Delivery of Bioactive Components in Nutraceuticals and Functional Foods. Crit Rev Food Sci Nutr 2009;49:577-606McClements DJ, Decker EA, Park Y, Weiss J. Structural Design Principles for Delivery of Bioactive Components in Nutraceuticals and Functional Foods. Crit Rev Food Sci Nutr 2009; 49: 577-606
Mercader J, Ribot J, Murano I, Felipe F, Cinti S, Bonet ML, Palou A. Remodeling of white adipose tissue after retinoic acid administration in mice. Endocrinology 2006;147:53255332Mercader J, Ribot J, Murano I, Felipe F, Cinti S, Bonet ML, Palou A. Remodeling of white adipose tissue after retinoic acid administration in mice. Endocrinology 2006; 147: 53255332
The Third Korea National Health and Nutrition Examination Survey (KNHANES Ⅲ) 2005, Korea Centers for Disease Control and Prevention.The Third Korea National Health and Nutrition Examination Survey (KNHANES III) 2005, Korea Centers for Disease Control and Prevention.
Moraru CI, Panchapakesan CP, Huang QR, Takhistov P, Liu S, Kokini JL. Nanotechnology: A new frontier in food science. Food Technol 2003;57:24-29Moraru CI, Panchapakesan CP, Huang QR, Takhistov P, Liu S, Kokini JL. Nanotechnology: A new frontier in food science. Food Technol 2003; 57: 24-29
Park HS. The approach to obesity and medical therapy at primary medical examination. Arch Family Med 2001;22:447-458Park HS. The approach to obesity and medical therapy at primary medical examination. Arch Family Med 2001; 22: 447-458
Walker CG, Zariwala MG, Holness MJ, Sugden MC. Diet, obesity and diabetes: a current update. Clin Sci ( Lond ) 2007;112:93111Walker CG, Zariwala MG, Holness MJ, Sugden MC. Diet, obesity and diabetes: a current update. Clin Sci ( Lond ) 2007; 112: 93111
Weiss J, Takhistov P, Mcclements DJ. Functional Materials in Food Nanotechnology. J Food Sci 2006;71:R107-R116Weiss J, Takhistov P, Mcclements DJ. Functional Materials in Food Nanotechnology. J Food Sci 2006; 71: R107-R116
World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
최근 공중보건에 있어, 영양부족, 감염성 질환 등에 의한 것 보다 오히려 과체중, 비만 등에 의한 것의 심각성이 날로 더해 가고 있다. 이와 같은 최근의 공중문제를 해결하기 위한 하나의 방안으로 본 발명의 기능성식품 및 그의 제조방법을 발명하기에 이르렀다.
Recently, in public health, the seriousness of overweight, obesity, etc. rather than malnutrition, infectious diseases, etc. is increasing day by day. One way to solve such a recent public problem has come to invent the functional food of the present invention and its manufacturing method.
한편, 본 발명이 이루고자 하는 기술적 과제들은 이상에서 언급한 기술적 과제들로 제한되지 않으며, 언급되지 않은 또 다른 기술적 과제들은 본 발명의 기재로부터 당해 분야에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다. On the other hand, the technical problem to be achieved by the present invention is not limited to the above-mentioned technical problems, other technical problems that are not mentioned can be clearly understood by those skilled in the art from the description of the present invention. There will be.
상기한 목적을 달성하기 위해 본 발명에서는 올레오레진 캡시컴(Oleoresin Capsicum)을 함유한 알긴산 이중층(Double-layers) 나노에멀젼의 체지방 분해용 조성물을 제공한다.
In order to achieve the above object, the present invention provides a composition for body fat decomposition of alginate double-layers nanoemulsion containing oleoresin capsicum (Oleoresin Capsicum).
또한 본 발명에서는 올레오레진 캡시컴 및 Tween 80을 섞어 혼합액을 제조하는 제1단계; 및 상기 혼합액과 알긴산 용액을 섞어 이중층(double layers) 나노에멀젼을 제조하는 제2단계;를 포함하는 체지방 분해용 조성물의 제조방법을 제공한다.
In the present invention, the first step of preparing a mixed solution by mixing the oleoresin capsicum and
바람직하게는, 상기 제1단계의 혼합액의 섞는 비율은 올레오레진 캡시컴 : Tween 80 = 1 : 3 인 것을 특징으로 할 수 있다.
Preferably, the mixing ratio of the mixed solution of the first step may be characterized in that the oleoresin capsicum:
바람직하게는, 상기 제2단계의 혼합액의 농도는 0.5%(w/v)인 것을 특징으로 할 수 있다.
Preferably, the concentration of the mixed solution of the second step may be characterized in that 0.5% (w / v).
바람직하게는, 상기 나노에멀젼을 교반 후, 여과하는 제3단계;를 더 포함하는 것을 특징으로 할 수 있다.
Preferably, after stirring the nanoemulsion, the third step of filtering; may be characterized in that it further comprises.
바람직하게는, 상온에서 안정화시키는 제4단계;를 더 포함하는 것을 특징으로 할 수 있다.
Preferably, the fourth step of stabilizing at room temperature; may be characterized in that it further comprises.
바람직하게는, 상기 교반은 1.9~2.1시간인 것을 특징으로 할 수 있다.
Preferably, the stirring may be characterized in that 1.9 to 2.1 hours.
바람직하게는, 상기 상온은 15~25℃인 것을 특징으로 할 수 있다.Preferably, the room temperature may be characterized in that 15 ~ 25 ℃.
본 발명인 본 발명은 올레오레진 캡시컴(Oleoresin Capsicum)을 함유한 알긴산 이중층(Double-layers) 나노에멀젼의 체지방 분해용 조성물 및 그의 제조방법에 따르면, 과체중, 비만 등에 의한 최근 보건 문제를 해소할 수 있다는 유리한 효과가 인정된다.According to the present invention, a composition for decomposing body fat of an alginate double-layers nanoemulsion containing an oleoresin capsicum and a method for preparing the same can solve the recent health problems caused by overweight and obesity. The beneficial effect is that it is recognized.
도 1은 세포 생존율에 관한 것이다.
도 2은 지질 축적율에 관한 것이다.
도 3은 유리지방산에 관한 것이다.
도 4은 CEBP-알파(상대적 유전자 발현), PPAR-감마(상대적 유전자 발현), aP2(상대적 유전자 발현)에 관한 것이다.
도 5은 HSL(상대적 유전자 발현), CPT-1알파(상대적 유전자 발현), UCP2(상대적 유전자 발현)에 관한 것이다.
도 6은 본 발명의 개략도이다.1 relates to cell viability.
2 relates to lipid accumulation rates.
3 relates to free fatty acids.
4 relates to CEBP-alpha (relative gene expression), PPAR-gamma (relative gene expression), aP2 (relative gene expression).
5 relates to HSL (relative gene expression), CPT-1 alpha (relative gene expression), UCP2 (relative gene expression).
6 is a schematic diagram of the present invention.
본 발명은 올레오레진 캡시컴(Oleoresin Capsicum)을 함유한 알긴산 이중층(Double-layers) 나노에멀젼의 체지방 분해용 조성물에 관한 것이다.
The present invention relates to a composition for body fat decomposition of an alginate double-layers nanoemulsion containing oleoresin capsicum.
또한 본 발명은 올레오레진 캡시컴 및 Tween 80을 섞어 혼합액을 제조하는 제1단계; 및 상기 혼합액과 알긴산 용액을 섞어 이중층(double layers) 나노에멀젼을 제조하는 제2단계;를 포함하는 체지방 분해용 조성물의 제조방법에 관한 것이다.
In another aspect, the present invention comprises the first step of preparing a mixed solution by mixing the oleoresin capsicum and
바람직하게는, 상기 제1단계의 혼합액의 섞는 비율은 올레오레진 캡시컴 : Tween 80 = 1 : 3 인 것을 특징으로 할 수 있고, 상기 제2단계의 혼합액의 농도는 0.5%(w/v)인 것을 특징으로 할 수 있다.
Preferably, the mixing ratio of the mixed solution of the first step may be characterized in that the oleoresin capsicum:
바람직하게는, 상기 나노에멀젼을 교반 후, 여과하는 제3단계;를 더 포함하는 것을 특징으로 할 수 있고, 나아가 상온에서 안정화시키는 제4단계;를 더 포함하는 것을 특징으로 할 수 있다. 상기 교반은 1.9~2.1시간인 것을 특징으로 할 수 있고, 상기 상온은 15~25℃인 것을 특징으로 할 수 있다.
Preferably, the third step of filtering, after stirring the nanoemulsion; may be characterized in that it further comprises, and further comprising a fourth step of stabilizing at room temperature. The stirring may be characterized in that 1.9 to 2.1 hours, the room temperature may be characterized in that 15 to 25 ℃.
이하에서 첨부된 도면을 참조한 실시예에 의거하여 구체적으로 설명한다.
Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.
1. 재료 및 방법1. Materials and Methods
(1) 재료의 구입(1) purchase of materials
본 연구에 사용된 oleoresin capsicum(OC, from Capsicum fruitscens L., SHU 100,000, India)은 (주) G&F에서 공급받았으며, 4℃에 보관하여 사용하였다. Alginate(from Macrocystis pyrifera, medium viscosity, Mw 240,000)는 Sigma사(USA)에서 구입하여 사용하였다.
The oleoresin capsicum (OC, from Capsicum fruitscens L. , SHU 100,000, India) used in this study was supplied by G & F Co., Ltd. and stored at 4 ℃. Alginate (from Macrocystis pyrifera, medium viscosity, Mw 240,000) was purchased from Sigma (USA).
(2) 나노에멀젼 제조(2) Nanoemulsion Preparation
알긴산(alginate)을 이용한 나노에멀젼은 자기결합 방법을 이용하여 제조하였다. 올레오레진 캡시컴과 Tween 80의 최적 배합비율(질량비)은 pseudo-ternary phase diagram에 의하여 1:3으로 결정하였다. 물(distilled water)을 연속상으로 제조한 나노에멀젼(distilled water nanoemusion)은 단일층(single layer) 나노에멀젼으로 분류하였으며, 알긴산을 연속상으로 제조한 나노에멀젼(alginate nanoemulsion)은 이중층(double layers) 나노에멀젼으로 분류하였다. 올레오레진 캡시컴과 Tween 80 혼합액을 0.5%(w/v) 농도로 물, 알긴산 용액에 각각 첨가하여 상온에서 2시간 동안 교반하여 단일층과 이중층 나노에멀젼을 제조하였다. 제조된 나노에멀젼은 0.45 μm PVDF filter(Whatman, England)로 여과하여 24시간동안 상온에서 안정화시킨 다음 사용하였다.
Nanoemulsion using alginate was prepared using a magnetic coupling method. The optimal mixing ratio (mass ratio) of oleoresin capsicum and
(3) 3T3-L1 지방세포 배양 및 분화 유도(3) 3T3-L1 adipocyte culture and differentiation induction
Murine 3T3-지방세포는 DMEM 배양액(Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum (Life Technologies, MD), 100 mM HEPES, 50 IU penicillin, and 50㎍ streptomycin/ml)에서 2×103 cell/cm2의 배율로 plating하였다. 3T3-지방세포의 분화를 위하여 3T3-지방세포가 약 60%의 confluency를 나타낼 때 10㎍/ml insulin, 0.25μM dexamethasone, 0.5mM 1-methyl-3-isobutylwanthine을 첨가시킨 DMEM 배양액으로 2일간 지방세포 분화를 유도한 다음 10% FBS-DMEM 배양액에서 7일간 배양하여 80% 이상 지방 입자 축적을 확인하였다.
Murine 3T3-fat cells were 2 × 10 3 cells / cm in DMEM culture (Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum (Life Technologies, MD), 100 mM HEPES, 50 IU penicillin, and 50 μg streptomycin / ml). Plated at a magnification of 2 . For the differentiation of 3T3-fat cells, when 3T3-fat cells showed a confluency of about 60%, fat cells were treated with DMEM medium containing 10 μg / ml insulin, 0.25 μM dexamethasone, and 0.5 mM 1-methyl-3-isobutylwanthine for 2 days. Differentiation was induced and then cultured in 10% FBS-DMEM culture for 7 days to confirm the accumulation of fat particles of 80% or more.
(4) 세포독성 평가(4) Cytotoxicity Assessment
올레오레진 캡시컴 나노에멀젼의 세포독성 측정은 CCK-8 kit(Dojindo, Japan)를 이용하여 측정하였다. 각 세포의 증식속도를 고려하여 적정수의 세포를 10% fetal bovine serum을 함유한 배지에 부유시켜 seeding하였다. 즉 3T3-L1 세포는 1×103 세포수로 96-well plate에 seeding하여 24시간 배양하였다. 올레오레진 캡시컴 나노에멀젼 시료, 단일층 나노에멀젼과 알긴산 이중층 나노에멀젼은 0.1ng/ml, 1㎍/ml, 10㎍/ml, 100㎍/ml이 되도록 첨가하고 시료 당 각각의 실험군은 96 well piate에서 동일한 조건으로 사용하였으며 37℃, 5% CO2 incubator에서 48시간 배양하였다. 여기에 CCK-용액 10㎕를 각 well에 첨가하여 2시간 더 배양시킨 다음 microplate reader로 450nm에서 흡광도를 측정하였다. 각 세포에 대한 독성은 각각의 대조군 3well의 평균 흡광도 값을 구하여 평균 흡광도 값에 대한 백분율로 나타내었다.
Cytotoxicity of oleoresin capsicum nanoemulsion was measured using CCK-8 kit (Dojindo, Japan). In consideration of the growth rate of each cell, the appropriate number of cells were seeded by floating in a medium containing 10% fetal bovine serum. That is, 3T3-L1 cells were seeded in 96-well plates with 1 × 10 3 cells and incubated for 24 hours. The oleoresin capsicum nanoemulsion sample, single layer nanoemulsion and alginic acid bilayer nanoemulsion were added at 0.1ng / ml, 1µg / ml, 10µg / ml, 100µg / ml and each experimental group was 96 wells. The same conditions were used for piate and incubated for 48 hours in a 37 ° C., 5% CO 2 incubator. 10 μl of CCK-solution was added to each well, followed by further incubation for 2 hours, and the absorbance was measured at 450 nm using a microplate reader. Toxicity for each cell was expressed as a percentage of the mean absorbance values obtained from the average absorbance value of each control 3well.
(5) 세포 내 지질 염색 및 정량(5) Intracellular Lipid Staining and Quantitation
3T3-L1 지방세포는 PBS로 세척하고 10% formalin/PBS(pH 7.4)에서 세포를 고정하였다. 그다음 0.6% Oil Red O를 이용하여 축적된 지방을 염색하였다. 염색된 지방 함량을 측정하기위해서 4% Nonidet P-4가 포함된 용액으로 용해하여 분광광도계를 이용하여 520nm에서 흡광도를 측정하였다. 각 염색된 지방 함량은 각각의 대조군 3 well의 평균 흡광도 값을 구하여 평균 흡광도 값에 대한 백분율로 나타내었다.
3T3-L1 adipocytes were washed with PBS and fixed in 10% formalin / PBS pH 7.4. The accumulated fat was then stained using 0.6% Oil Red O. To measure dyed fat content, the solution was dissolved in a solution containing 4% Nonidet P-4 and the absorbance was measured at 520 nm using a spectrophotometer. Each stained fat content was expressed as a percentage of the average absorbance values obtained from the average absorbance value of each
(6) 세포 내 중성지방 농도(6) triglyceride concentration in cells
세포내의 중성지방 농도는 상업용 키트 (Asan Pharm, Korea)를 이용하여 측정하였다. 세포양의 표준화를 위한 단백질 함량은 bicinchoninic acid (BCA) protein assay (Thermo Scientific, USA) kit를 사용하여 정량하였다.
Intracellular triglyceride concentration was measured using a commercial kit (Asan Pharm, Korea). Protein content for normalization of cell volume was quantified using a bicinchoninic acid (BCA) protein assay (Thermo Scientific, USA) kit.
(7) Real-time quantitative PCR(7) Real-time quantitative PCR
총 RNA는 TRIzol(Gibco)을 이용하여 추출하였으며 추출한 총 RNA로부터 cDNA를 합성하기 위한 reverse transcription의 반응조건은 다음과 같다. 5Xbuffer, 1mM dNTPs, 30pmole oligo dT19, 200U M-MLV (moloney-murine leukemia virus reverse transcriptase, Promega)이 포함된 총 volume 20㎕에 4㎍ total RNA를 혼합하여 37℃에서 1시간, 70℃에서 15분간 반응시켰다. 각각의 cDNA 1㎕를 2X SYBR Green PCR master mix(Qiagen), 0.25μM primer와 반응시켰다. 증폭은 Rotor-Gene RG-3000A (Corbett Research)으로 사용하고, real- time PCR의 반응조건은 95℃ 15분, 95℃ 15초(denaturation), 56℃ 30초(annealing), 72℃ 30초(extension)로 하였다. 정량분석을 위한 형광 측정은 매 PCR cycle 마다 측정되었으며 유전자 발현에 대한 상대적인 정량은 delta-delta Ct 방법을 이용하여 수행하였다.
Total RNA was extracted using TRIzol (Gibco) and the reaction conditions of reverse transcription to synthesize cDNA from the extracted total RNA are as follows. 4 μg total RNA was mixed with 20 μl of total volume containing 5Xbuffer, 1 mM dNTPs, 30 pmole oligo dT19, and 200 U M-MLV (moloney-murine leukemia virus reverse transcriptase, Promega). Reacted. 1 μl of each cDNA was reacted with 2 × SYBR Green PCR master mix (Qiagen) and 0.25 μM primer. Amplification was performed using Rotor-Gene RG-3000A (Corbett Research), and the reaction conditions of real-time PCR were 95 ° C 15 minutes, 95 ° C 15 seconds (denaturation), 56 °
(8) Free fatty acid와 glycerol 정량(8) Free fatty acid and glycerol determination
분화된 3T3-L1 지방세포는 2% (wt/vol) fatty acid-free bovine serum albumin (BSA)가 포함한 DMEM에서 밤새 배양하였다. 그 다음날 올레오레진 캡시컴 나노에멀젼을 처리하여 24시간동안 배양하였다. 세포로부터 방출된 배양액을 수집한 다음 65℃에서 8분동안 열을 가하여 세포로부터 방출된 효소의 활성을 정지시켰다. 글리세롤 함량은 glycerol analysis kit (Roche Molecular Biochemicals)에 의해 측정하였고 유리지방산은 acyl-CoA oxidase-based colorimetric kit(NEFA-C; WAKO Pure Chemicals)에 의해 분석하였다. protein 함량을 측정하여 세포양의 표준화 하였다.
Differentiated 3T3-L1 adipocytes were cultured overnight in DMEM containing 2% (wt / vol) fatty acid-free bovine serum albumin (BSA). The next day, the oleoresin capsicum nanoemulsion was treated and incubated for 24 hours. The cultures released from the cells were collected and heat was applied at 65 ° C. for 8 minutes to stop the activity of the enzymes released from the cells. Glycerol content was measured by glycerol analysis kit (Roche Molecular Biochemicals) and free fatty acids were analyzed by acyl-CoA oxidase-based colorimetric kit (NEFA-C; WAKO Pure Chemicals). Protein content was measured and normalized to cell volume.
(9) 통계분석(9) Statistical Analysis
각 실험의 결과는 SPSS(통계 프로그램)에 의하여 실험군의 평균과 표준 편차를 계산하고, 각 실험군의 분석항목별 차이는 one-way ANOVA로 사전 검증한 후 Duncan's multiple range test를 이용하여 P < 0.05 수준에서 유의성을 검증하였다.
The results of each experiment were calculated using the SPSS (statistical program) to calculate the mean and standard deviation of the experimental group, and the difference of each analysis item was pre-verified by one-way ANOVA and then P <0.05 level using Duncan's multiple range test. The significance was verified at.
2. 결과 및 고찰2. Results and discussion
(1) 실험예(1) Experimental Example
올레오레진 캡시컴 나노에멀젼으로 지방분해효과를 파악해 보기 위하여 올레오레진 캡시컴 나노에멀젼의 세포독성을 측정하였고, 올레오레진 캡시컴 나노에멀젼의 지방축적 억제효과를 측정하였으며, 중성지방 분해산물인 유지지방산과 글리세롤 함량분석을 통한 지방분해 효과를 측정하였을 뿐만 아니라, 올레오레진 캡시컴 나노에멀젼에 의한 지방합성 및 지방분해 관련 유전자 발현 효과를 측정하여 다음과 같이 그 결과를 나타냈다.
To determine the lipolytic effect of oleoresin capsicum nanoemulsion, we measured the cytotoxicity of oleoresin capcicom nanoemulsion and measured the fat accumulation inhibitory effect of oleoresin capcicom nanoemulsion. In addition to measuring the fat degradation effect through the analysis of fatty acid and glycerol content, the effects of liposynthesis and lipolysis related gene expression by oleoresin capsicum nanoemulsion were measured and the results were as follows.
(1_1) 올레오레진 캡시컴 나노에멀젼의 세포독성 측정(1_1) Cytotoxicity Measurement of Oleoresin Capsicum Nanoemulsion
3T3-L1 지방세포에서 올레오레진 캡시컴 나노에멀젼의 세포독성을 측정하기 위하여 단일층 나노에멀젼과 알긴산 이중층 나노에멀젼을 0.1ng/ml, 1ng/ml, 10ng/ml, 100ng/ml, 1000ng/ml의 농도로 각각 포함된 배양액에서 4시간, 24시간 배양한 후 CCK-8 kit를 이용하여 측정하였다. 그 결과 올레오레진 캡시컴의 단일층 나노에멀젼과 알긴산 이중층 나노에멀젼모두 세포독성이 나타나지 않았다(도 1a, 도 1b 참조).
In order to measure the cytotoxicity of oleoresin capsicum nanoemulsion in 3T3-L1 adipocytes, monolayer nanoemulsion and alginic acid bilayer nanoemulsion were 0.1ng / ml, 1ng / ml, 10ng / ml, 100ng / ml, 1000ng / ml After incubation for 4 hours and 24 hours in each of the culture solution contained in the concentration of was measured using a CCK-8 kit. As a result, both monolayer nanoemulsion and alginic acid bilayer nanoemulsion of oleoresin capsicum did not show cytotoxicity (see FIGS. 1A and 1B).
(1_2) 올레오레진 캡시컴 나노에멀젼의 지질축적 억제 효과(1_2) Inhibition of Lipid Accumulation by Oleoresin Capsicum Nanoemulsion
올레오레진 캡시컴 나노에멀젼에 의한 지질축적 억제 효과를 측정하기 위해 올레오레진 캡시컴의 단일층 나노에멀젼과 알긴산 이중층 나노에멀젼을 3T3-L1 지방세포에 시간별(1시간, 3시간, 6시간, 12시간, 24시간)로 처리하였다. 시간별 지방세포 내 지질 함량 변화는 올레오레진 캡시컴 나노에멀젼 1000 ng/ml을 처리하여 1, 3, 6, 12 및 24 시간 배양 후 oil-red O 염색에 의해 세포내 지방 함량으로 분석하였다. 시간별 지방세포 내 지질 함량 변화는 알긴산 이중층 나노에멀젼 1000 ng/ml을 처리하여 3, 6, 12 및 24 시간 배양하였을 때 단일층 나노에멀젼에 비해 각각 5.6%, 5.5%, 10.5% 및 20.2%의 지방세포 내 지질 함량이 감소하였다(도 2a 참조).
To measure the effect of lipid accumulation by oleoresin capsicum nanoemulsion, monolayer nanoemulsion and alginic acid bilayer nanoemulsion of oleoresin capsicum were applied to 3T3-L1 adipocytes by hour (1 hour, 3 hours, 6 hours, 12 hours, 24 hours). Changes in lipid content in adipocytes over time were analyzed by intracellular fat content by oil-red O staining after 1, 3, 6, 12 and 24 hours incubation with 1000 ng / ml oleoresin capsicum nanoemulsion. Changes in lipid content in adipocytes over time were 5.6%, 5.5%, 10.5%, and 20.2% fat, respectively, compared to monolayer nanoemulsions after 3, 6, 12, and 24 hours of treatment with 1000 ng / ml of alginic acid bilayer nanoemulsions. Intracellular lipid content was reduced (see FIG. 2A).
시간별 지방세포 내 중성지방 함량 또한 알긴산 이중층 나노에멀젼 1000 ng/ml을 처리하여 6, 12 및 24 시간 배양하였을 때 단일층 나노에멀젼에 비해 각각 5.4%, 10.9% 및 22.4%의 지방세포 내 중성지방 함량이 감소하였다(도 2b 참조).
The triglyceride content in adipocytes by time was also 5.4%, 10.9% and 22.4% in triglyceride content compared to monolayer nanoemulsions when treated with 1000 ng / ml of alginic acid bilayer nanoemulsions for 6, 12 and 24 hours, respectively. This decreased (see Figure 2b).
(1_3) 올레오레진 캡시컴 나노에멀젼의 지방분해 효과(1_3) Lipolytic Effects of Oleoresin Capsicum Nanoemulsion
지방세포에 저장되어 있는 중성지방은 유리지방산과 글리세롤로 가수 분해되어 혈액 속으로 방출된다. 올레오레진 캡시컴 나노에멀젼에 의한 지방분해 효과를 측정하기 위해 올레오레진 캡시컴 나노에멀젼을 3T3-L1 지방세포에 시간별(1, 3, 6, 12 및 24 시간)로 처리한 후 세포 밖으로 방출된 지방 분해 산물인 유리지방산과 글리세롤 함량을 측정하였다. 시간별 지방세포 배양액으로 방출된 유리지방산 함량 변화는 알긴산 이중층 나노에멀젼 1000 ng/ml을 처리하여 6, 12 및 24 시간 배양하였을 때 단일층 나노에멀젼에 비해 각각 8.4%, 13.6% 및 25.8%의 유리지방산 함량이 증가하였다(도 3a 참조). 시간별 글리세롤 함량 변화 또한 알긴산 이중층 나노에멀젼 1000 ng/ml을 처리하여 6, 12 및 24 시간 배양하였을 때 단일층 나노에멀젼에 비해 각각 5.7%, 15.2% 및 30.32%의 글리세롤 함량이 증가하였다(도 3b 참조).
Triglycerides stored in adipocytes are hydrolyzed into free fatty acids and glycerol and released into the blood. To measure the lipolytic effect of oleoresin capsicum nanoemulsion, oleoresin capcicom nanoemulsion was released to cells after treatment with 3T3-L1 adipocytes hourly (1, 3, 6, 12 and 24 hours). The free fatty acid and glycerol contents were measured. Changes in free fatty acid content released into adipocyte cultures by time were 8.4%, 13.6%, and 25.8% of free fatty acids, respectively, when treated with 1000 ng / ml of alginic acid bilayer nanoemulsions for 6, 12, and 24 hours. The content increased (see FIG. 3A). Changes in glycerol content over time also resulted in an increase in glycerol content of 5.7%, 15.2% and 30.32%, respectively, when treated with 1000 ng / ml of alginic acid bilayer nanoemulsions for 6, 12 and 24 hours of incubation (see FIG. 3b). ).
(1_4) 올레오레진 캡시컴 나노에멀젼에 의한 지방합성과 지방분해 관련 유전자 발현 효과(1_4) Effects of Liposynthesis and Lipolysis-related Gene Expression by Oleoresin Capsicum Nanoemulsion
지방세포에서 올레오레진 캡시컴 나노에멀젼에 의한에 의한 지방분해 관련 유전자 발현량 변화를 측정하였다. 올레오레진 캡시컴의 단일층 나노에멀젼과 알긴산 이중층 나노에멀져을 농도별(0, 1, 10, 100 및 1000 ng/ml)로 처리하여 24시간 배양 후 지방합성 및 지방분해에 관여하는 유전자의 발현량을 비교하였다. 지방조직에서 지방축적에 관여하는 perioxisome proliferator activated receptors-gamma(PPAR-r), CCAAT/enhancer-binding protein-alpha(CEBP-a)와 adipocyte fatty acid binding protein(aP2)유전자와 지방분해 및 지방산화에 관여하는 hormone sensitive lipase (HSL), carnitine palmitoyltransferase-1(CPT-1)과 uncoupling protein-2(UCP-2) 유전자의 발현량은 real-time PCR로 분석하였다. 알긴산 이중층 나노에멀젼 처리하였을 때 단일층 나노에멀젼에 비해 지방합성 관련 유전자 PPAR-r, CEBP-a, aP2 발현량은 농도가 높을수록 감소하였고(도 4 참조), 지방분해 관련 유전자 HSL, CPT-1과 UCP-2 발현량은 농도가 높을수록 증가하였다(도 5 참조).
Changes in the amount of gene expression associated with lipolysis by oleoresin capsicum nanoemulsion in adipocytes were measured. The monolayer nanoemulsion and the alginic acid bilayer nanoemulsion of oleoresin capsicum were treated in different concentrations (0, 1, 10, 100 and 1000 ng / ml) to determine the genes involved in liposynthesis and lipolysis after 24 hours of incubation. Expression levels were compared. Perioxisome proliferator activated receptors-gamma (PPAR-r), CCAAT / enhancer-binding protein-alpha (CEBP-a) and adipocyte fatty acid binding protein (aP2) genes involved in fat accumulation in adipose tissue The expression levels of hormone sensitive lipase (HSL), carnitine palmitoyltransferase-1 (CPT-1) and uncoupling protein-2 (UCP-2) genes were analyzed by real-time PCR. When the alginic acid bilayer nanoemulsion was treated, the expression levels of the liposynthesis related genes PPAR-r, CEBP-a, and aP2 decreased compared to the monolayer nanoemulsion (see FIG. 4), and the lipolysis related genes HSL and CPT-1. And UCP-2 expression increased with increasing concentration (see FIG. 5).
3. 결론3. Conclusion
본 연구결과는 올레오진 캡시컴을 함유한 알긴산 이중층 나노에멀젼이 지방세포 내 지질축적을 억제하고, 세포내 중성지방 분해를 촉진하여 세포 밖으로 유리지방산과 글리세롤 방출량을 증가시킨다. 올레오진 캡시컴을 함유한 알긴산 이중층 나노에멀젼은 단일층 지방합성에 관여하는 유전자 PPAR-r, CEBP-a와 aP2 발현량을 감소시키고, 지방분해에 관여하는 유전자 HSL과 지방산화에 관여하는 유전자 CPT-1과 UCP-2 발현량은 증가시켰다. 따라서 본 연구결과는 올레오진 캡시컴을 함유한 알긴산 이중층 나노에멀젼이 체지방 분해에 유용한 새로운 기능성 식품 또는 의약품으로 사용될 수 있음을 시사하고 있다.
The present results suggest that alginate bilayer nanoemulsions containing olegin capsicum inhibit lipid accumulation in adipocytes and promote intracellular triglyceride breakdown to increase free fatty acid and glycerol release from cells. Alginate bilayer nanoemulsion containing olegin capsicum reduces the expression levels of genes PPAR-r, CEBP-a and aP2 involved in monolayer liposynthesis, genes HSL involved in lipolysis, and genes CPT involved in fatty acidization -1 and UCP-2 expression levels were increased. Therefore, the results suggest that alginic acid bilayer nanoemulsion containing olegin capsicum can be used as a novel functional food or medicine useful for body fat breakdown.
이상 본 발명의 구체적 실시형태와 관련하여 본 발명을 설명하였으나 이는 예시에 불과하며 본 발명은 이에 제한되지 않는다. 당업자는 본 발명의 범위를 벗어나지 않고 설명된 실시형태를 변경 또는 변형할 수 있으며, 이러한 변경 또는 변형도 본 발명의 범위에 속한다. 또한, 본 명세서에서 설명한 각 구성요소의 물질은 당업자가 공지된 다양한 물질로부터 용이하게 선택하여 대체할 수 있다. 또한 당업자는 본 명세서에서 설명된 구성요소 중 일부를 성능의 열화 없이 생략하거나 성능을 개선하기 위해 구성요소를 추가할 수 있다. 뿐만 아니라, 당업자는 공정 환경이나 장비에 따라 본 명세서에서 설명한 방법 단계의 순서를 변경할 수도 있다. 따라서 본 발명의 범위는 설명된 실시형태가 아니라 특허청구범위 및 그 균등물에 의해 결정되어야 한다.
Although the present invention has been described in connection with the specific embodiments of the present invention, it is to be understood that the present invention is not limited thereto. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. In addition, the materials of each component described herein can be readily selected and substituted for various materials known to those skilled in the art. Those skilled in the art will also appreciate that some of the components described herein can be omitted without degrading performance or adding components to improve performance. In addition, those skilled in the art may change the order of the method steps described herein depending on the process environment or equipment. Therefore, the scope of the present invention should be determined by the appended claims and equivalents thereof, not by the embodiments described.
Claims (8)
Alginate double-layers nanoemulsion composition for body fat decomposition containing oleoresin capsicum.
A first step of preparing a mixed solution by mixing an oleoresin capsicum and Tween 80; And a second step of preparing the double layer nanoemulsion by mixing the mixed solution and the alginic acid solution.
The method of claim 2, wherein the mixing ratio of the mixed solution of the first step is oleoresin capsicum: Tween 80 = 1: 3.
The method of claim 2, wherein the concentration of the mixed solution of the second step is 0.5% (w / v).
The method of claim 2, further comprising: filtering the nanoemulsion and then filtering the nanoemulsion.
The method of claim 5, further comprising stabilizing at room temperature.
The method of claim 5, wherein the stirring is 1.9 to 2.1 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120024467A KR20130103101A (en) | 2012-03-09 | 2012-03-09 | Composition for body fat lipolysis using alginate double-layers nanoemulsions containing oleoresin capsicum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120024467A KR20130103101A (en) | 2012-03-09 | 2012-03-09 | Composition for body fat lipolysis using alginate double-layers nanoemulsions containing oleoresin capsicum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130103101A true KR20130103101A (en) | 2013-09-23 |
Family
ID=49452586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120024467A Ceased KR20130103101A (en) | 2012-03-09 | 2012-03-09 | Composition for body fat lipolysis using alginate double-layers nanoemulsions containing oleoresin capsicum |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20130103101A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101539688B1 (en) * | 2015-04-30 | 2015-07-27 | 주식회사 씨에이팜 | Cosmetic effective in improving skin photoaging containing oleoresin capsicum and manufacturing method thereof |
| KR20190016216A (en) * | 2017-08-08 | 2019-02-18 | 한국식품연구원 | manufacturing method of nanoemulsion composition containing quercein and nanoemulsion composition containing quercein prepared using the method |
| US10668123B2 (en) | 2015-04-27 | 2020-06-02 | Omniactive Health Technologies Limited | Capsicum compositions and uses thereof |
-
2012
- 2012-03-09 KR KR1020120024467A patent/KR20130103101A/en not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10668123B2 (en) | 2015-04-27 | 2020-06-02 | Omniactive Health Technologies Limited | Capsicum compositions and uses thereof |
| KR101539688B1 (en) * | 2015-04-30 | 2015-07-27 | 주식회사 씨에이팜 | Cosmetic effective in improving skin photoaging containing oleoresin capsicum and manufacturing method thereof |
| KR20190016216A (en) * | 2017-08-08 | 2019-02-18 | 한국식품연구원 | manufacturing method of nanoemulsion composition containing quercein and nanoemulsion composition containing quercein prepared using the method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abdel Aziz et al. | Antihyperglycemic effects and mode of actions of Musa paradisiaca leaf and fruit peel hydroethanolic extracts in nicotinamide/streptozotocin‐induced diabetic rats | |
| Kim et al. | Anti-obesity effect of extract from fermented Curcuma longa L. through regulation of adipogenesis and lipolysis pathway in high-fat diet-induced obese rats | |
| Jung et al. | Hypoglycemic effects of a phenolic acid fraction of rice bran and ferulic acid in C57BL/KsJ-db/db mice | |
| Cao et al. | Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes | |
| Kang et al. | Sasa quelpaertensis Nakai extract and its constituent p-coumaric acid inhibit adipogenesis in 3T3-L1 cells through activation of the AMPK pathway | |
| Zhu et al. | Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice | |
| Kanagasabapathy et al. | AMP-activated protein kinase mediates insulin-like and lipo-mobilising effects of β-glucan-rich polysaccharides isolated from Pleurotus sajor-caju (Fr.), Singer mushroom, in 3T3-L1 cells | |
| Valli et al. | Modulation of adipocyte differentiation and proadipogenic gene expression by sulforaphane, genistein, and docosahexaenoic acid as a first step to counteract obesity | |
| Garcia-Diaz et al. | Vitamin C inhibits leptin secretion and some glucose/lipid metabolic pathways in primary rat adipocytes | |
| CN101310718A (en) | Composition containing catechin for reducing weight and blood fat and use thereof | |
| Kim et al. | Esculetin, a coumarin derivative, suppresses adipogenesis through modulation of the AMPK pathway in 3T3-L1 adipocytes | |
| Zar Kalai et al. | Antiobesity Effects of an Edible Halophyte Nitraria retusa Forssk in 3T3‐L1 Preadipocyte Differentiation and in C57B6J/L Mice Fed a High Fat Diet‐Induced Obesity | |
| Hong et al. | Capsinoids suppress fat accumulation via lipid metabolism | |
| Budluang et al. | Anti‐inflammatory and anti‐insulin resistance activities of aqueous extract from Anoectochilus burmannicus | |
| Ko et al. | Prunus mume and Lithospermum erythrorhizon extracts synergistically prevent visceral adiposity by improving energy metabolism through potentiating hypothalamic leptin and insulin signalling in ovariectomized rats | |
| Jackson et al. | Structural constraints and importance of caffeic acid moiety for anti‐hyperglycemic effects of caffeoylquinic acids from chicory | |
| Dort et al. | Beneficial effects of cod protein on skeletal muscle repair following injury | |
| Pérez-Ramírez et al. | Effect of Ocimum sanctum and Crataegus pubescens aqueous extracts on obesity, inflammation, and glucose metabolism | |
| Han et al. | (‐)‐Hydroxycitric acid nourishes protein synthesis via altering metabolic directions of amino acids in male rats | |
| Im et al. | Mechanisms of blood glucose-lowering effect of aqueous extract from stems of Kothala himbutu (Salacia reticulata) in the mouse | |
| JP5171097B2 (en) | Heparin-binding epidermal growth factor-like growth factor gene expression promoter containing plant extract | |
| Pomilio et al. | Dietary anthocyanins balance immune signs in osteoarthritis and obesity–update of human in vitro studies and clinical trials | |
| Oowatari et al. | Wasabi leaf extracts attenuate adipocyte hypertrophy through PPARγ and AMPK | |
| Liu et al. | Leptin pathway is a crucial target for anthocyanins to protect against metabolic syndrome | |
| Liao et al. | Pea protein hydrolysate reduces blood glucose in high-fat diet and streptozotocin-induced diabetic mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20120309 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130710 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20140202 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130710 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |